ClinicalTrials.gg
TerminatedNCT02670330Updated Sep 27, 2019Results posted

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

A Phase 3 interventional study of SD-101-6.0 cream in Epidermolysis Bullosa, sponsored by Scioderm, Inc.. Terminated at 30 sites in 12 countries. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2019-09-27.

Sponsored by Scioderm, Inc. (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment

Why this study was terminated
The Sponsor voluntarily recalled SD-101 and terminated the study due to GMP deficiencies identified during an FDA inspection at the site of the manufacturer.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Not applicable
Ages
1 Month and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Epidermolysis Bullosa with a site in United States — 10 open to participants now, 13 under way, 3 of them phase 3. Epidermolysis Bullosa · United States.

Enrollment
3rd of 37
152 · median 16
Started
2015
with 1 other
Phase 3
8 of 42
1 open now
Registered
11th of 42
by date
Lead sponsor
4 of 42
Scioderm, Inc.

Among the 42 studies in Epidermolysis Bullosa with a site in United States, this one is the 3rd largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 in phase 3, and was the 11th registered.

Epidermolysis Bullosa

86 studies on the registry are indexed under Epidermolysis Bullosa; 18 are open to participants now.

Browse Epidermolysis Bullosa studies →

Open to participants now

10 of the 42 studies in Epidermolysis Bullosa with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Epidermolysis Bullosa studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 1 Month and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Epidermolysis Bullosa with a site in United States, or all of them as a file.
02

Study summary

The study aimed to assess the long-term safety of topical use of Zorblisa (SD-101-6.0) in participants with Epidermolysis Bullosa (EB).

Read the detailed description

This was an open label, multi-center extension study to assess the long-term safety of topically applied SD-101-6.0 in participants with simplex, recessive dystrophic, and junctional non-Herlitz EB. SD-101-6.0 was applied topically once a day to the entire body. The planned duration of treatment with SD-101-6.0 for Study SD-006 was up to 48 months, with a safety follow-up period of 30 days; however, the study was terminated early by the sponsor. The maximum study duration completed by at least 1 participant, treatment and safety follow-up, was 37 months.

Participants who successfully completed Study SD-005 had the option to rollover into Study SD-006. The screening/baseline visit (Visit 1) occurred at Visit 5 (approximately 90 days from baseline) of Study SD-005. The Body Surface Area (BSA) assessments of lesional skin and wound burden performed at Visit 5 (approximately 90 days from baseline) for Study SD-005 were utilized as the baseline assessments for Study SD-006. Participants returned for follow-up visits at Month 1 then every 3 months.

At each visit, assessments included BSA of lesional skin and wound burden. For target wounds that are not closed by the end of Study SD-005, the ARANZ picture and calculation of target wound area at the final visit for Study SD-005 was used as the baseline area size of the target wound for Study SD-006. These unhealed target wounds from Study SD-005 were assessed via ARANZ SilhouetteStar™ at each subsequent scheduled visit until the target wound was documented as closed. Closed wounds were assessed for scarring.

03

Conditions studied

  • Epidermolysis Bullosa

Browse trials for

Keywords

  • Amicus Therapeutics
  • Scioderm, Inc.
  • Simplex
  • Recessive Dystrophic
  • Junctional non-Herlitz
  • Epidermolysis Bullosa
  • SD-101 6%
  • SD-101-6.0
  • Allantoin 6%
  • Zorblisa
04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Form signed by the participant or participant's legal representative; if the participant was under the age of 18 but capable of providing assent, signed assent from the participant.
  • Participant (or caretaker) must have been willing to comply with all protocol requirements.
  • Participants who completed the SD-005 study (on study drug at Visit 5, approximately 90 days from baseline).

Exclusion criteria

Exclusion Criteria:

  • Participants who did not meet the entry criteria outlined above.
  • Pregnancy or breastfeeding during the study. (A urine pregnancy test was performed at the final visit for Study SD-005 for female participants of and repeated at screening/baseline visit of Study SD-006 if these visits did not occur on the same day).
  • Female participants of childbearing potential who were not abstinent or not practicing a medically acceptable method of .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Experimental: SD-101-6.0 cream

    All participants (or their caregivers) applied SD-101-6.0 cream topically once a day to the entire body for a period of up to 36 months.

    Drug: SD-101-6.0 cream

Interventions

  • SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.

    Also known as: Zorblisa, SD-101

06

What researchers measure

Primary outcomes

  1. Number Of Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAEs were defined as adverse events that started or worsened on or after baseline visit.

    Time frame: From baseline to 30 days after last application of study drug (up to a maximum of 37 months)

Secondary outcomes

  1. Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin Up To Month 30

    Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. The percentage, ranging from 0% to 100%, of affected body surface area (BSA) was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions to calculate the BSAI that would range from 0% to 100%. The BSA for lesional skin was to be assessed by the same study physician on each visit for a particular participant. The mean change from baseline in BSAI was assessed every 3 months. Only participants with data available for analysis at each time point are presented.

    Time frame: Baseline, up to Month 30

  2. Change From Baseline In BSAI Of Total Body Wound Burden Up To Month 30

    A wound was defined as an open area on the skin (that is, epidermal covering disrupted). Total body wound burden was calculated using BSAI; the percentage, ranging from 0% to 100%, of affected BSA was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions to calculate the BSAI that would range from 0% to 100%. The BSAI for total body wound burden was to be assessed by the same study physician at each visit for a particular participant. The mean change from baseline in total body wound burden was assessed every 3 months. Only participants with data available for analysis at each time point are presented.

    Time frame: Baseline, up to Month 30

07

Results

Posted Aug 2, 2019
Limitations and caveats
Results are presented for all participants who received SD-101-6.0 before the early termination of the study on 4 June 2018. The maximum study duration completed by at least 1 participant was 37 months.

Participant flow

152 participants with epidermolysis bullosa (EB) were enrolled between 9 June 2015 and 5 July 2017 in this open-label, multi-center extension study. All enrolled participants had previously completed Study SD-005 (NCT02384460).

Participant flow — Overall Study
MilestoneSD-101-6.0 to SD-101-6.0Placebo to SD-101-6.0
Started7577
Received at least 1 dose of study drug7577
Completed00
Not completed7577
Withdrew: Protocol deviation10
Withdrew: Study terminated by sponsor3643
Withdrew: Adverse event13
Withdrew: Withdrawal by subject3429
Withdrew: Lost to follow-up32

Outcome measures

PrimaryNumber Of Participants With Treatment Emergent Adverse Events (TEAEs)

TEAEs were defined as adverse events that started or worsened on or after baseline visit.

Time frame:
From baseline to 30 days after last application of study drug (up to a maximum of 37 months)
Reported as:
Count of participants · Participants
Number Of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsSD-101-6.0 to SD-101-6.0Placebo to SD-101-6.0
Any TEAE5158
Any TEAE Related To Study Drug817
Any Fatal TEAE00
Any Serious TEAE1114
Any TEAE Leading To Discontinuation23
SecondaryChange From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin Up To Month 30

Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. The percentage, ranging from 0% to 100%, of affected body surface area (BSA) was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions to calculate the BSAI that would range from 0% to 100%. The BSA for lesional skin was to be assessed by the same study physician on each visit for a particular participant. The mean change from baseline in BSAI was assessed every 3 months. Only participants with data available for analysis at each time point are presented.

Time frame:
Baseline, up to Month 30
Reported as:
Mean · Percentage of BSAI
Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin Up To Month 30
Percentage of BSAISD-101-6.0 to SD-101-6.0Placebo to SD-101-6.0
Month 1-0.76 ± 4.185-0.54 ± 5.398
Month 3-1.87 ± 5.999-1.21 ± 6.457
Month 6-1.77 ± 6.015-1.35 ± 6.813
Month 9-2.48 ± 9.4360.31 ± 10.117
Month 12-3.35 ± 9.5660.44 ± 10.327
Month 15-1.90 ± 7.3372.15 ± 12.546
Month 18-2.46 ± 5.275-4.24 ± 8.207
Month 21-3.06 ± 5.869-1.58 ± 10.442
Month 24-1.63 ± 5.647-0.64 ± 5.981
Month 27-1.87 ± 4.405-0.16 ± 6.514
Month 30-2.77 ± 5.4653.37 ± 10.706
SecondaryChange From Baseline In BSAI Of Total Body Wound Burden Up To Month 30

A wound was defined as an open area on the skin (that is, epidermal covering disrupted). Total body wound burden was calculated using BSAI; the percentage, ranging from 0% to 100%, of affected BSA was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions to calculate the BSAI that would range from 0% to 100%. The BSAI for total body wound burden was to be assessed by the same study physician at each visit for a particular participant. The mean change from baseline in total body wound burden was assessed every 3 months. Only participants with data available for analysis at each time point are presented.

Time frame:
Baseline, up to Month 30
Reported as:
Mean · Percentage of BSAI
Change From Baseline In BSAI Of Total Body Wound Burden Up To Month 30
Percentage of BSAISD-101-6.0 to SD-101-6.0Placebo to SD-101-6.0
Month 1-1.75 ± 4.8910.07 ± 4.044
Month 3-1.52 ± 5.343-0.80 ± 3.001
Month 6-1.54 ± 4.322-0.48 ± 3.595
Month 9-1.82 ± 6.083-0.42 ± 3.586
Month 12-1.38 ± 5.497-0.13 ± 3.211
Month 15-0.15 ± 4.5110.26 ± 3.030
Month 18-1.12 ± 3.053-1.31 ± 4.665
Month 21-1.44 ± 3.150-0.28 ± 5.507
Month 24-0.68 ± 3.890-0.01 ± 2.898
Month 27-0.43 ± 2.9240.31 ± 3.615
Month 30-1.55 ± 2.8831.69 ± 5.933

Adverse events

Collected over From baseline to 30 days after last application of study drug (up to a maximum of 37 months).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SD-101-6.0 to SD-101-6.00/75 (0%)11/75 (14.7%)44/75 (58.7%)
Placebo to SD-101-6.00/77 (0%)14/77 (18.2%)51/77 (66.2%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventSD-101-6.0 to SD-101-6.0Placebo to SD-101-6.0
AnaemiaBlood and lymphatic system disorders1/752/77
Oesophageal stenosisGastrointestinal disorders1/752/77
Skin infectionInfections and infestations0/752/77
PericarditisCardiac disorders1/750/77
Congenital megaureterCongenital, familial and genetic disorders1/750/77
KeratitisEye disorders1/750/77
ConstipationGastrointestinal disorders1/751/77
DysphagiaGastrointestinal disorders1/750/77
FaecalomaGastrointestinal disorders1/750/77
Implant site infectionInfections and infestations1/750/77
Most frequent other events
Showing 10 of 49
Most frequent other events
EventSD-101-6.0 to SD-101-6.0Placebo to SD-101-6.0
Skin infectionInfections and infestations6/7512/77
NasopharyngitisInfections and infestations10/756/77
PyrexiaGeneral disorders5/7510/77
Wound infectionInfections and infestations3/756/77
PruritusSkin and subcutaneous tissue disorders3/756/77
AnaemiaBlood and lymphatic system disorders5/755/77
ConstipationGastrointestinal disorders5/753/77
BronchitisInfections and infestations5/751/77
Upper respiratory tract infectionInfections and infestations4/755/77
Wound infection bacterialInfections and infestations2/755/77

Baseline characteristics

Intent-to-treat (ITT) population: all participants who rolled over from Study SD-005.

Age, Continuous
Age, Continuous(years)SD-101-6.0 to SD-101-6.0Placebo to SD-101-6.0Total
Mean14.18 ± 13.38114.36 ± 13.59914.27 ± 13.447
Sex: Female, Male
Sex: Female, Male(Participants)SD-101-6.0 to SD-101-6.0Placebo to SD-101-6.0Total
Female284573
Male473279
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SD-101-6.0 to SD-101-6.0Placebo to SD-101-6.0Total
Hispanic or Latino51318
Not Hispanic or Latino6760127
Unknown or Not Reported347
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SD-101-6.0 to SD-101-6.0Placebo to SD-101-6.0Total
White/Caucasian6563128
Black or African-American437
Asian3710
American Indian or Alaskan Native000
Native Hawaiian or Other Pacific000
Other112
Unknown235
EB Type
EB Type(Participants)SD-101-6.0 to SD-101-6.0Placebo to SD-101-6.0Total
Simplex9716
Recessive Dystrophic5356109
Junctional Non-Herlitz131427
08

Study locations

30 sites
  • Phoenix, Arizona 85016, United States
  • Redwood City, California 94063, United States
  • Aurora, Colorado 80045, United States
  • Washington, District of Columbia 20016, United States
  • Chicago, Illinois 60611, United States
  • Minneapolis, Minnesota 55455, United States
  • Columbia, Missouri 65212, United States
  • Saint Louis, Missouri 63110, United States
  • East Setauket, New York 11733, United States
  • Chapel Hill, North Carolina 27516, United States
  • Cincinnati, Ohio 45229-3039, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Charleston, South Carolina 29425-5780, United States
  • San Antonio, Texas 78218, United States
  • Seattle, Washington 98105, United States
  • Kogarah, New South Wales 2217, Australia
  • Parkville, Victoria 3052, Australia
  • Salzburg, 5020, Austria
  • Nice, 1-06202, France
  • Paris, 75015, France
  • Toulouse, France
  • Freiburg im Breisgau, 79104, Germany
  • Hannover, 30173, Germany
  • Tel Aviv, Israel
  • Kaunas, LT-50009, Lithuania
  • Groningen, 9713 GZ, Netherlands
  • Warsaw, Poland
  • Belgrade, Serbia
  • Madrid, Spain
  • London, WC1N 3JH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Sep 2018, 38 months.

Results were first posted in Aug 2019, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2015
First posted
Feb 1, 2016
StartActual
Jun 9, 2015
Primary completionActual
Sep 3, 2018
CompletionActual
Sep 3, 2018
Results first posted
Aug 2, 2019
Last update
Sep 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02670330
Lead sponsor
Scioderm, Inc.
Collaborators
Amicus Therapeutics
Responsible party
Sponsor
First posted
Feb 1, 2016
Start date
Jun 9, 2015
Primary completion
Sep 3, 2018
Completion
Sep 3, 2018
Results posted
Aug 2, 2019
Last update
Sep 27, 2019

Study contacts

Medical Monitor
study director · Amicus Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nelitolimod

Start the discussion